Regen completes preclinical experimentation for its NR2F6 checkpoint inhibitor
26 February 2016 | By Victoria White
Regen has recently filed two patent applications covering the molecular pathways activated by NR2F6 silencing...
List view / Grid view
26 February 2016 | By Victoria White
Regen has recently filed two patent applications covering the molecular pathways activated by NR2F6 silencing...
18 February 2016 | By Victoria White
The results demonstrate that suppression of NR2F6 in T-cells results in increased expression of key immune stimulatory proteins IL-17 and IL-18...
20 January 2016 | By Victoria White
The collaboration will focus on identifying ligands for NR2F6 using Regen's screening methodology and the expertise and unique chemical libraries of NCATS...
12 November 2015 | By Victoria White
The studies will evaluate the utilisation of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients...
10 July 2015 | By Victoria White
Regen BioPharma has reported the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate...